John Ha1, Melissa Yan1, Maria Aguilar1, Taft Bhuket2, Michele M Tana3, Benny Liu2, Robert G Gish4,5, Robert J Wong2. 1. Department of Medicine, Alameda Health System-Highland Hospital, Oakland, California. 2. Division of Gastroenterology and Hepatology, Alameda Health System-Highland Hospital, Oakland, California. 3. Division of Gastroenterology, Department of Medicine, University of California-San Francisco, San Francisco, California. 4. Division of Gastroenterology and Hepatology, Stanford Health Care, Stanford, California. 5. Hepatitis B Foundation, Doylestown, Pennsylvania.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the fastest rising causes of cancer-related deaths in the United States, with disparities observed in cancer incidence and survival between ethnic groups. This report provides updated analyses on race-specific disparities in US HCC trends. METHODS: This large, population-based cohort study was conducted using Surveillance, Epidemiology, and End Results cancer registry data from 2003 to 2011 to investigate race-specific disparities in HCC incidence and survival. Survival was analyzed using Kaplan-Meier methods and multivariate Cox proportional-hazards models. RESULTS: From 2003 to 2011, Asians had the highest HCC incidence, followed by blacks, Hispanics, and non-Hispanic whites. During the same period, Hispanics had the greatest increase in HCC incidence (+35.8%), whereas Asians experienced a 5.5% decrease. Although patients aged ≥65 years had the highest HCC incidence among all racial/ethnic groups, the higher HCC incidence in Asians was observed only for patients ages <50 and ≥65 years, whereas HCC incidence among patients ages 50 to 64 years was similar among Asians, blacks, and Hispanics. The overall 5-year HCC survival rate was highest among Asians (26.1%; 95% confidence interval [CI], 24.5%-27.6%) and lowest among blacks (21.3%; 95% CI, 19.5%-23.1%). On multivariate regression, Asians (hazard ratio, 0.83; 95% CI, 0.79-0.87; P < .001) and blacks (hazard ratio, 0.94; 95% CI, 0.89-0.99; P = .01) had significantly higher survival compared with non-Hispanic whites. CONCLUSIONS: Asians were the only group to demonstrate a declining HCC incidence in the form of a shift from advanced HCC to more localized HCC. These findings most likely reflect improved screening and surveillance efforts for this group. Cancer 2016;122:2512-23.
BACKGROUND:Hepatocellular carcinoma (HCC) is one of the fastest rising causes of cancer-related deaths in the United States, with disparities observed in cancer incidence and survival between ethnic groups. This report provides updated analyses on race-specific disparities in US HCC trends. METHODS: This large, population-based cohort study was conducted using Surveillance, Epidemiology, and End Results cancer registry data from 2003 to 2011 to investigate race-specific disparities in HCC incidence and survival. Survival was analyzed using Kaplan-Meier methods and multivariate Cox proportional-hazards models. RESULTS: From 2003 to 2011, Asians had the highest HCC incidence, followed by blacks, Hispanics, and non-Hispanic whites. During the same period, Hispanics had the greatest increase in HCC incidence (+35.8%), whereas Asians experienced a 5.5% decrease. Although patients aged ≥65 years had the highest HCC incidence among all racial/ethnic groups, the higher HCC incidence in Asians was observed only for patients ages <50 and ≥65 years, whereas HCC incidence among patients ages 50 to 64 years was similar among Asians, blacks, and Hispanics. The overall 5-year HCC survival rate was highest among Asians (26.1%; 95% confidence interval [CI], 24.5%-27.6%) and lowest among blacks (21.3%; 95% CI, 19.5%-23.1%). On multivariate regression, Asians (hazard ratio, 0.83; 95% CI, 0.79-0.87; P < .001) and blacks (hazard ratio, 0.94; 95% CI, 0.89-0.99; P = .01) had significantly higher survival compared with non-Hispanic whites. CONCLUSIONS: Asians were the only group to demonstrate a declining HCC incidence in the form of a shift from advanced HCC to more localized HCC. These findings most likely reflect improved screening and surveillance efforts for this group. Cancer 2016;122:2512-23.
Authors: Nicole E Rich; Caitlin Hester; Mobolaji Odewole; Caitlin C Murphy; Neehar D Parikh; Jorge A Marrero; Adam C Yopp; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2018-05-31 Impact factor: 11.382
Authors: Sherean Farvardin; Jaimin Patel; Maleka Khambaty; Olutola A Yerokun; Huram Mok; Jasmin A Tiro; Adam C Yopp; Neehar D Parikh; Jorge A Marrero; Amit G Singal Journal: Hepatology Date: 2016-10-01 Impact factor: 17.425
Authors: Amit G Singal; Jasmin A Tiro; Jorge A Marrero; Katharine McCallister; Caroline Mejias; Brian Adamson; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm Journal: Gastroenterology Date: 2016-11-05 Impact factor: 22.682
Authors: Shoshana Adler Jaffe; Orrin Myers; Angela L W Meisner; Charles L Wiggins; Deirdre A Hill; Jean A McDougall Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-12-03 Impact factor: 4.254
Authors: Meera Sangaramoorthy; Juan Yang; Mindy C DeRouen; Chanda Ho; Ma Somsouk; Michele M Tana; Caroline A Thompson; Joseph Gibbons; Scarlett Lin Gomez; Salma Shariff-Marco Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-11-12 Impact factor: 4.254
Authors: Emmanuel Gabriel; Jin Kim; Katherine T Ostapoff; Kristopher Attwood; Sergei Kurenov; Boris Kuvshinoff; Steven N Hochwald; Steven J Nurkin Journal: J Gastrointest Oncol Date: 2018-04